title: Health-related quality of life in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.
abstract: Reduced-intensity conditioning allogeneic HSCT (RIC) has less regimen-related morbidity and mortality than myeloablative allogeneic HSCT (MT) offering allogeneic transplantation to patients otherwise excluded. Whether these advantages improve health-related quality of life (HRQL) is unknown. We examined the HRQL effects of RIC and MT in patients with hematological diseases pre-transplant (baseline), days 0, 30, 100, 1 and 2 years following HSCT. HRQL was measured using the Short Form-36 Health Survey and the Functional Assessment of Cancer Therapy - General and BMT. Data were analyzed using mixed linear modeling adjusting for baseline HRQL differences. Patients (RIC=41, MT=35) were predominately male (67%), in remission/stable disease (65%) with an Eastern Cooperative Oncology Group status <or=1 (97%). HRQL progressively improved (P<0.01) in both groups with higher scores at day 100 compared to days 0 and 30; there was no difference between groups during early recovery. At 2 years, all survivors (n=43) reported HRQL similar or better than baseline. Results suggest RIC and MT patients experience a similar pattern of HRQL improvement during early recovery. Two-year survivors report a return to baseline or better in HRQL by day 100, with the exception of physical health in MT patients.
authors.affiliation: Department of Nursing, National Institutes of Health, Bethesda, MD 20892, USA. mbevans@cc.nih.gov
authors.forename: M F
authors.initials: MF
authors.lastname: Bevans
authors.forename: S
authors.initials: S
authors.lastname: Marden
authors.forename: N K
authors.initials: NK
authors.lastname: Leidy
authors.forename: K
authors.initials: K
authors.lastname: Soeken
authors.forename: G
authors.initials: G
authors.lastname: Cusack
authors.forename: P
authors.initials: P
authors.lastname: Rivera
authors.forename: H
authors.initials: H
authors.lastname: Mayberry
authors.forename: M R
authors.initials: MR
authors.lastname: Bishop
authors.forename: R
authors.initials: R
authors.lastname: Childs
authors.forename: A J
authors.initials: AJ
authors.lastname: Barrett
mesh_terms: D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D006801:Humans; D008297:Male; D008875:Middle Aged; D009316:National Institutes of Health (U.S.); D017063:Outcome Assessment, Health Care; D011446:Prospective Studies; D011788:Quality of Life; D018434:Sickness Impact Profile; D015996:Survival Rate; D017741:Survivors; D014184:Transplantation, Homologous; D014481:United States